A dose finding study of fluvastatin for in vivo demonstration of inhibiting hepatitis C replication in patients infected with chronic hepatitis C with special attention to the African-American population.
Phase of Trial: Phase II
Latest Information Update: 26 Jul 2012
At a glance
- Drugs Fluvastatin (Primary)
- Indications Hepatitis C
- Focus Pharmacodynamics
- 26 Jul 2012 Official title ammended and additional lead trial centre added as reported by ClinicalTrials.gov record.
- 26 Jul 2012 Actual end date (September 2007) added as reported by ClinicalTrials.gov.
- 06 Apr 2007 New trial record.